Aerie Completes Enrollment In Phase 3 Registration Trial Of Rhopressa

(RTTNews) - Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company, Tuesday announced the completion of enrollment in the company's 400-patient Phase 3 registration trial, Rocket 1, of Rhopressa.

Rhopressa is a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure or IOP in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial, Rocket 2, will measure efficacy over three months.

The primary efficacy endpoint of the trials is to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol.

Timolol is the most widely used comparator in registration trials for glaucoma. In addition, the company is conducting a safety-only study in Canada, named Rocket 3.